BiotechTube

HRS-4642 + AG + HRS-4642 placebo + AG

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

Conditions

KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

Trial Timeline

Dec 1, 2025 → Apr 1, 2029

NCT ID
NCT07232875

About HRS-4642 + AG + HRS-4642 placebo + AG

HRS-4642 + AG + HRS-4642 placebo + AG is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07232875. Target conditions include KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07232875Phase 3Recruiting

Competing Products

20 competing products in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

See all competitors
ProductCompanyStageHype Score
HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for InfusionJiangsu Hengrui MedicinePhase 1/2
41
HRS-6093Jiangsu Hengrui MedicinePhase 1
33
HRS-4642Jiangsu Hengrui MedicinePhase 1
33
Pembrolizumab + TrametinibMerckPhase 1
33
Opnurasib + TNO155 + trametinib + cetuximab + tislelizumabNovartisPhase 1/2
41
JDQ443 + TNO155 + tislelizumabNovartisPhase 1/2
41
JDQ443 + trametinib + Ribociclib + cetuximabNovartisPhase 1/2
41
JDQ443NovartisPhase 2
52
Trametinib + Anlotinib + TislelizumabNovartisPhase 1/2
41
AMG 510AmgenPhase 1
32
AMG 510 + DocetaxelAmgenPhase 3
76
Epirubicine, Oxaliplatin, Capecitabine, PanitumumabAmgenPhase 2
51
AMG 410 + Pembrolizumab + PanitumumabAmgenPhase 1
32
sotorasib + Anti PD-1/L1 + MidazolamAmgenPhase 1/2
40
MEK162 and mFOLFIRIPfizerPhase 1
32
IBI351+AK112Innovent BiologicsPhase 2
51
GFH925Innovent BiologicsPhase 1/2
40
Momelotinib (MMB) + TrametinibGSK plcPhase 1
32
BAY3498264BayerPhase 1
30
ARV-806ArvinasPhase 1/2
36

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85